Sionna Therapeutics Reports Topline Data from Clinical Trials and Updates Corporate Strategy

Sionna Therapeutics, Inc. (Nasdaq: SION) announced topline data from its PreciSION CF Phase 2a trial of SION-719 and its Phase 1 trial of SION-451-based dual combinations. The company stated it will not advance SION-719 as an add-on to standard of care and plans to preserve capital while evaluating next steps for its SION-451 program.